What is betulinic acid and where does it come from?

Betulinic acid is a naturally occurring pentacyclic triterpenoid compound found in highest concentrations in the bark of white birch trees (Betula species), where it can constitute up to 1.9% of dry bark weight in some species. It also occurs in smaller amounts in pears, apples, rosemary, and tropical plants such as Uapaca species from Cameroon, and can be produced semi-synthetically by oxidizing betulin, a closely related compound abundant in birch bark.

Does betulinic acid kill cancer cells?

In laboratory (in vitro) studies, betulinic acid has shown potent selective cytotoxicity against a wide range of human cancer cell lines, including 91% inhibition of prostate (DU-145), 92% of breast (MCF-7), and 84% of lung (A549) cells at 100 µM, with IC50 values as low as 2.10 µg/ml against certain leukemia lines. However, no human clinical trials have been conducted, so it is not possible to conclude that it kills cancer cells in living humans; all evidence remains preclinical.

What is the recommended dose of betulinic acid?

No standardized or clinically validated human dose for betulinic acid has been established, as human clinical trials have not been completed. Preclinical research uses concentrations of 1–100 µM in cell cultures, but these figures cannot be directly extrapolated to human supplemental doses without pharmacokinetic data; anyone considering use should consult a healthcare provider and be aware that human safety and efficacy remain unproven.

Is betulinic acid the same as betulin?

Betulinic acid and betulin are distinct but closely related triterpenoid compounds found in birch bark; betulin (lup-20(29)-ene-3β,28-diol) is more abundant and features two hydroxyl groups, while betulinic acid (3β-hydroxy-lup-20(29)-en-28-oic acid) has a carboxylic acid at C-28 in place of one hydroxyl. Betulinic acid can be produced by chemical oxidation of betulin, and both compounds co-occur in birch bark extracts, though betulinic acid is considered the more pharmacologically active of the two in anticancer and antiviral contexts.

What are the side effects of betulinic acid?

No human clinical safety data exists for betulinic acid, so a complete side effect profile cannot be established; preclinical in vitro and animal studies have not identified major toxicity at pharmacologically relevant concentrations, and the compound shows selectivity for cancer cells over normal cells in laboratory models. Given the complete absence of human trial data, the compound's poor oral bioavailability, and theoretical drug interaction risks with chemotherapeutics, immunosuppressants, and anticoagulants, its use in humans—particularly during pregnancy or lactation—is not currently recommended outside of controlled clinical research settings.

How does betulinic acid work against cancer cells differently than chemotherapy drugs?

Betulinic acid induces apoptosis (programmed cell death) in cancer cells through a mitochondrial pathway that is distinct from conventional chemotherapy mechanisms, potentially offering a different approach for drug-resistant cancers. Unlike many traditional chemotherapy agents, betulinic acid has demonstrated selectivity for malignant cells while sparing normal healthy cells in preclinical studies, which may result in fewer side effects. This targeted mechanism makes it particularly interesting for combination therapy strategies alongside existing cancer treatments.

What foods naturally contain betulinic acid, and can diet provide therapeutic amounts?

Betulinic acid is found naturally in the bark of birch trees and in smaller amounts in various plants including basil, oregano, and some medicinal mushrooms, but dietary sources cannot reliably deliver the concentrations used in research studies (typically 2.10–9.5 µg/ml in cell studies). The betulinic acid content in food sources is too variable and insufficient to achieve the bioactive levels demonstrated in preclinical anticancer research. Supplementation remains the primary method to obtain potentially therapeutic doses of this compound.

Is betulinic acid effective against drug-resistant cancer cells?

Preliminary research suggests betulinic acid may be effective against certain drug-resistant cancer cell lines due to its mitochondrial-targeting apoptosis pathway, which differs from mechanisms that cancer cells commonly develop resistance to. However, human clinical trials demonstrating efficacy against resistant cancers in patients are still limited, and more research is needed to confirm these promising preclinical findings. Any potential use against drug resistance should only be pursued under medical supervision as part of an approved clinical trial.

Betulinic Acid

Betulinic acid is a pentacyclic triterpenoid that integrates into lipid bilayers, induces apoptosis in cancer cells via mitochondrial pathways, and exerts antioxidant activity through DPPH radical scavenging with an IC50 of 23.75 µg/ml. Preclinical in vitro data shows selective cytotoxicity against multiple cancer cell lines—including 91% inhibition in prostate (DU-145) and 92% in breast (MCF-7) cells at 100 µM—though no human clinical trials have been completed to confirm these effects.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Betulinic acid is a pentacyclic triterpenoid found in highest concentrations in the bark of white birch trees (Betula alba and related Betula species), native to temperate and boreal regions of Europe, Asia, and North America. It is also present in smaller quantities in pears, apples, rosemary, and tropical species such as Uapaca species in Cameroon, where bark concentrations can reach up to 1.9% by dry weight. Traditionally, birch bark has been harvested from naturally growing trees rather than cultivated plantations, with the compound extracted via methanol, ethanol, or methylene chloride-methanol solvent systems, or produced by chemical oxidation of the related compound betulin.

Historical & Cultural Context

Birch bark, the primary botanical source of betulinic acid, has been used for centuries in Northern European, Siberian, and Indigenous North American healing traditions, primarily for its antimicrobial, wound-healing, and anti-inflammatory properties, though the specific compound responsible was not isolated until modern phytochemical analysis. In Chinese folk medicine, Uapaca and related species containing betulinic acid were employed for antiparasitic and antimicrobial purposes, while Vietnamese practitioners used Orthosiphon stamineus—another BA-containing plant—as a diuretic and renal tonic. South American traditional healers in Argentina utilized legume species containing related triterpenoids for anti-infective applications, reflecting convergent ethnobotanical knowledge across geographically disparate cultures. Betulinic acid itself was first chemically characterized and isolated in the early twentieth century, with its significant anticancer properties identified by the National Cancer Institute in the 1990s, sparking a wave of preclinical oncology research that continues today.

Health Benefits

- **Anticancer Cytotoxicity**: Betulinic acid selectively induces apoptosis in malignant cells across multiple cancer types, with IC50 values of 2.10–2.60 µg/ml against leukemia lines (WEHI-3B, HL-60) and EC50 values of 5–9.5 µg/ml for breast, lung, and colorectal lines, while largely sparing normal cells in preclinical models.
- **Antioxidant Activity**: It scavenges free radicals in a dose-dependent manner, achieving 88.67% DPPH radical inhibition at 50 µg/ml and suppressing lipid peroxidation by 16.25–90.2% across a concentration range of 10–250 µg/ml, mimicking the endogenous antioxidant bilirubin.
- **Antiviral Properties**: Betulinic acid interferes with viral replication and membrane fusion events for several enveloped viruses, including HIV-1, where derivatives have demonstrated activity by blocking gp41-mediated viral entry in preclinical assays.
- **Antimicrobial Activity**: It exhibits antibacterial effects against Gram-positive organisms, producing an 18.8 mm² inhibition zone against Bacillus subtilis at 1000 µg/disc, with dose-dependent activity emerging at concentrations ≥500 µg/disc.
- **Antiplasmodial Activity**: Betulinic acid shows activity against chloroquine-resistant Plasmodium falciparum with an IC50 of 19.6 µg/ml in vitro, suggesting potential utility in drug-resistant malaria contexts where new scaffolds are urgently needed.
- **Anti-inflammatory Potential**: Through inhibition of NF-κB signaling and reduction of pro-inflammatory cytokine expression in preclinical models, betulinic acid modulates inflammatory cascades relevant to chronic disease and tumor microenvironment progression.
- **Metabolic and Hepatoprotective Effects**: Emerging preclinical data suggest betulinic acid may attenuate hepatic lipid accumulation and oxidative stress markers, with ferric reducing antioxidant power (FRAP) assays confirming significant electron-donating capacity relevant to liver protection.

How It Works

Betulinic acid's hydrophobic pentacyclic lupane-type triterpenoid scaffold, featuring a carboxylic acid at C-28 and a hydroxyl group at C-3, allows it to integrate into lipid bilayers and interact with membrane-associated proteins, disrupting mitochondrial membrane potential and triggering the intrinsic apoptotic pathway through cytochrome c release, caspase-3 and caspase-9 activation, and PARP cleavage. It downregulates anti-apoptotic Bcl-2 family proteins while upregulating pro-apoptotic Bax, shifting the cellular balance toward programmed cell death selectively in transformed cells; this selectivity is hypothesized to arise from structural differences between tumor and normal cell membranes. At the antioxidant level, its functional hydroxyl and carboxyl groups donate hydrogen atoms to neutralize reactive oxygen species, scavenging DPPH, hydroxyl, and superoxide radicals in a manner analogous to bilirubin, while also chelating transition metal ions to inhibit Fenton-type lipid peroxidation chain reactions. Additionally, betulinic acid suppresses NF-κB nuclear translocation and inhibits topoisomerase activity, further contributing to its antiproliferative and anti-inflammatory effects observed in cell-based assays.

Scientific Research

The evidence base for betulinic acid consists almost entirely of in vitro cell line studies and limited animal model experiments; no peer-reviewed human clinical trials with defined sample sizes, randomization, or controlled designs have been published as of this entry. Preclinical studies demonstrate consistent cytotoxicity across a broad panel of cancer cell lines—lung (A549, 84% inhibition at 100 µM), prostate (DU-145, 91%), breast (MCF-7, 92%), leukemia (HL-60, IC50 8 µM at 48 h), and colorectal (RKO, EC50 9.5 µg/ml)—with potency comparable to reference agents adriamycin and 5-fluorouracil in side-by-side comparisons. Antiplasmodial and antimicrobial activities have been confirmed in multiple independent laboratory studies using standardized disc diffusion and parasite growth inhibition assays, lending mechanistic credibility, but translational relevance to humans remains unestablished. The compound's poor aqueous solubility and consequent low oral bioavailability represent a significant barrier to clinical development, and formulation strategies such as nanoencapsulation are under active preclinical investigation to address this limitation.

Clinical Summary

No human clinical trials evaluating betulinic acid as a therapeutic or supplemental agent have been reported in the peer-reviewed literature; all efficacy data originates from in vitro cell culture experiments and, to a limited extent, rodent models. The most robust in vitro outcomes include selective apoptosis induction in leukemia, prostate, breast, lung, and colorectal cancer lines at low micromolar concentrations (IC50 2.10–15.27 µg/ml depending on cell type and exposure duration), with cytotoxicity profiles broadly comparable to established chemotherapeutic agents in controlled comparisons. Antioxidant and antimicrobial endpoints have been reproduced across multiple independent laboratory groups using standardized assay conditions, increasing confidence in mechanism but not in clinical translatability. Until Phase I safety trials defining pharmacokinetics, maximum tolerated dose, and bioavailability in humans are conducted, the clinical significance of preclinical data cannot be determined with confidence.

Nutritional Profile

Betulinic acid is a pure secondary plant metabolite—a pentacyclic triterpenoid with molecular formula C30H48O3 and molecular weight 456.7 g/mol—and does not contribute macronutrients, vitamins, or minerals when consumed. In white birch bark extracts, it co-occurs with phenolic compounds including gallic acid (approximately 156.26 µg/mg extract), catechin (approximately 265.19 µg/mg extract), and the related triterpenoid betulin (approximately 56.83 µg/mg extract), which contribute to the overall antioxidant and bioactive profile of raw extracts. Betulinic acid itself appears as a white crystalline powder with a melting point of 307–310°C, is highly lipophilic (logP estimated >6), and has negligible aqueous solubility (<1 µg/ml in water), severely limiting passive intestinal absorption from dietary or supplemental sources without formulation enhancement. Bioavailability from whole plant consumption is expected to be extremely low; encapsulation in lipid carriers or cyclodextrins has been shown in rodent models to meaningfully improve systemic exposure.

Preparation & Dosage

- **Isolated Powder (Research Grade)**: Used at 1–100 µM in cell culture studies; no human supplemental dose is established or recommended.
- **Birch Bark Extract**: Standardized extracts containing quantified betulinic acid (alongside betulin) are available as botanical supplements, though standardization percentages vary widely between manufacturers and no regulatory standard exists.
- **Lipid-Based Formulations**: Preclinical encapsulation in nanoparticles, liposomes, or lipid carriers is under investigation to overcome hydrophobicity and improve oral bioavailability; these remain experimental.
- **Traditional Decoction**: Birch bark has been boiled in water or extracted in ethanol in traditional folk medicine systems; betulinic acid content in such preparations is low and poorly absorbed due to its lipophilicity.
- **Solvent Extraction (Laboratory)**: Isolation uses methanol, ethanol, or CH2Cl2-MeOH mixtures from bark or aerial plant parts; oxidation of betulin with chromium-based or enzymatic oxidants also yields betulinic acid.
- **Dosage Guidance**: No clinically validated human dose exists; practitioners should note that extrapolating µM concentrations from cell culture to human dosing is scientifically inappropriate without pharmacokinetic bridging studies.
- **Timing**: Not applicable given absence of clinical dosing protocols; lipid co-administration is theoretically advantageous based on absorption chemistry.

Synergy & Pairings

Betulinic acid is frequently co-extracted with catechins and gallic acid from birch bark, and in vitro evidence suggests these phenolic co-compounds may potentiate its antioxidant and cytotoxic effects through complementary radical-scavenging mechanisms and distinct pro-apoptotic signaling inputs, though formal synergy studies with defined ratios are limited. Formulation with phosphatidylcholine-based lipid carriers or piperine (from black pepper) is hypothesized to enhance oral bioavailability by improving solubilization and intestinal lymphatic uptake, paralleling strategies used successfully for other lipophilic triterpenoids such as ursolic acid. In oncology-oriented preclinical research, combination with conventional agents like 5-fluorouracil has demonstrated additive or potentially synergistic cytotoxicity against colorectal and lung cancer lines, though the mechanistic basis—likely non-overlapping apoptotic pathway engagement—requires further investigation before any clinical stack recommendation can be made.

Safety & Interactions

Human safety data for betulinic acid is virtually absent, as no clinical trials have been conducted to establish a safe dose range, maximum tolerated dose, or adverse event profile in human subjects, making definitive safety guidance impossible at this time. Preclinical in vitro and animal studies have not identified overt systemic toxicity at pharmacologically relevant concentrations, and the compound's selective cytotoxicity toward cancer cells over normal cells in cell culture models is considered a favorable safety signal, though this does not predict human tolerability. No clinically documented drug interactions have been established; however, given betulinic acid's modulation of apoptotic and NF-κB pathways, theoretical interactions with immunosuppressants, anticoagulants, and cytotoxic chemotherapy agents warrant caution and should be evaluated in any future clinical investigation. Pregnancy and lactation safety is entirely unknown; use should be avoided in these populations, and individuals with liver or kidney disease should exercise particular caution given the compound's lipophilicity and likely hepatic metabolism.